CSPC pharmaceutical's JMT206 antibody gets clinical trial green light

CSPC Pharmaceutical Group Limited announced on November 26, 2025, that its recombinant fully human anti-ActRIIA/IIB monoclonal antibody drug, JMT206, has received approval from the National Medical Products Administration of the People's Republic of China to commence clinical trials. This marks a key milestone for the product, which is designed for weight management in individuals with obesity or overweight conditions accompanied by at least one weight-related comorbidity.

JMT206 is engineered to simultaneously bind to activin receptor type IIA (ActRIIA) and type IIB (ActRIIB), effectively blocking activin A, myostatin (GDF8), and growth differentiation factor 11 (GDF11). This mechanism aims to inhibit downstream signaling, reduce muscle loss, and promote skeletal muscle growth, thereby increasing muscle mass and reducing fat. The drug also shows potential to enhance the efficacy of GLP-1 receptor agonists in weight loss outcomes.

Preclinical studies have demonstrated JMT206's high bioavailability, along with favorable efficacy and safety profiles, indicating its promising value for clinical development. The board of directors of CSPC Pharmaceutical Group Limited, led by chairman CAI Dong Chen, anticipates further progress in the clinical evaluation of this novel therapeutic.